Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM04ZUW)

Drug Name
Ponalrestat Drug Info
Synonyms
PONALRESTAT; statil; 72702-95-5; Ponalrestatum [Latin]; UNII-2CV0A5G64E; ICI-128436; ICI 128,436; CHEMBL7679; C17H12BrFN2O3; 2CV0A5G64E; 2-(3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid; NCGC00024824-01; 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid; 1-Phthalazineaceticacid, 3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-; Ponalrestatum; 1-Phthalazineacetic acid, 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-; Prodiax; Ponalrestat [USAN:BAN:INN]; ISIS-5GLT2rx
Cross-matching ID
PubChem CID
5278
ChEBI ID
CHEMBL7679
CAS Number
CAS 72702-95-5
TTD Drug ID
D0U9TM

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Type I diabetes mellitus 2.29 0.00e+0 38/43 (88.37%) PRF1;GZMB;PTPRN2;...
Allograft rejection 2.24 0.00e+0 32/38 (84.21%) PRF1;GZMB;IFNG;...
Graft-versus-host disease 2.18 0.00e+0 32/42 (76.19%) PRF1;GZMB;IFNG;...
Asthma 2.08 0.00e+0 25/31 (80.65%) RNASE3;PRG2;HLA-DPB1;...
Systemic lupus erythematosus 1.99 1.94e-3 45/135 (33.33%) CTSG;C2;IFNG;...
Viral protein interaction with cytokine and cytokine re... 1.96 1.62e-3 84/100 (84%) CXCL14;CXCL9;IL2RG;...
Antigen processing and presentation 1.86 9.72e-3 60/78 (76.92%) CD8A;CD8B;HSPA1A;...
Homologous recombination 1.85 8.50e-3 35/41 (85.37%) RPA3;BARD1;POLD2;...
DNA replication 1.79 1.73e-2 34/36 (94.44%) RPA3;POLD2;PRIM1;...
T cell receptor signaling pathway 1.75 2.72e-2 93/104 (89.42%) NFATC3;CD3D;LCP2;...
Natural killer cell mediated cytotoxicity 1.74 2.56e-2 99/131 (75.57%) PRF1;LCP2;KLRK1;...
Malaria 1.74 2.35e-2 44/50 (88%) THBS4;KLRK1;TLR4;...
Primary immunodeficiency 1.73 2.17e-2 33/38 (86.84%) IL2RG;CD3D;CD8A;...
Autoimmune thyroid disease 1.70 2.64e-2 46/53 (86.79%) PRF1;GZMB;HLA-DPB1;...
Pyrimidine metabolism 1.67 3.30e-2 40/56 (71.43%) RRM2;DCTPP1;DTYMK;...
Th1 and Th2 cell differentiation 1.67 3.22e-2 80/92 (86.96%) IL2RG;NFATC3;IL2RB;...
Mismatch repair 1.67 3.09e-2 22/23 (95.65%) RPA3;POLD2;RFC5;...
Inflammatory bowel disease 1.62 4.64e-2 58/65 (89.23%) IL2RG;TLR4;IFNG;...
Complement and coagulation cascades 1.61 4.81e-2 76/85 (89.41%) CFB;CLU;C2;...
Biosynthesis of unsaturated fatty acids -1.87 3.07e-2 21/27 (77.78%) HSD17B12;ELOVL1;HACD1;...
Steroid biosynthesis -2.27 0.00e+0 19/20 (95%) SOAT1;DHCR24;LSS;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H